Phase I Study of Low-Dose Fractionated Radiotherapy as a Chemosensitizer for Gemcitabine and Erlotinib in Patients With Locally Advanced or Limited Metastatic Pancreatic Cancer.
Phase of Trial: Phase I
Latest Information Update: 09 Mar 2017
At a glance
- Drugs Erlotinib (Primary) ; Gemcitabine (Primary)
- Indications Pancreatic cancer
- Focus Adverse reactions
- 24 Nov 2015 Status changed from active, no longer recruiting to completed.
- 10 Oct 2013 Planned end date changed from 1 Dec 2013 to 1 Dec 2014 as reported by ClinicalTrials.gov.
- 10 Oct 2013 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.